name: Genomic sequence panel with RNA analysis of 5-50 genes associated with hematolymphoid disorders, with mRNA expression levels


name: Solid organ or hematolymphoid neoplasm or disorder, 51 or greater genes, genomic sequence analysis panel, interrogation for sequence variants and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed


name: Genomic sequence analysis panel of DNA or combined DNA and RNA of 51 or more genes associated with blood and lymphatic system disorders


name: Genomic sequence analysis with DNA analysis of more than 50 genes associated with solid organ or hematolymphoid neoplasm or disorder


name: Genomic sequence analysis with DNA analysis of more than 50 genes associated with solid organ or hematolymphoid neoplasm or disorder, with interrogation for sequence variants and copy number variants and rearrangements


name: Genomic sequence analysis with DNA analysis of more than 50 genes associated with solid organ or hematolymphoid neoplasm or disorder, with isoform expression level


name: Genomic sequence analysis with DNA analysis of more than 50 genes associated with solid organ or hematolymphoid neoplasm or disorder, with mRNA expression level


name: Genomic sequence analysis with DNA and RNA analysis of more than 50 genes associated with solid organ or hematolymphoid neoplasm or disorder, with interrogation for sequence variants and copy variants and rearrangements


name: Genomic sequence analysis with DNA and RNA analysis of more than 50 genes associated with solid organ or hematolymphoid neoplasm or disorder, with isoform expression level


name: Genomic sequence analysis with DNA and RNA analysis of more than 50 genes associated with solid organ or hematolymphoid neoplasm or disorder, with mRNA expression level


name: Genomic sequence analysis with combined DNA and RNA analysis of more than 50 genes associated with solid organ or hematolymphoid neoplasm or disorder


name: Genomic sequence analysis panel of RNA of 51 or more genes associated with blood and lymphatic system disorders


name: Genomic sequence analysis with RNA analysis of more than 50 genes associated with solid organ or hematolymphoid neoplasm or disorder, with interrogation for isoform expression


name: Genomic sequence analysis with RNA analysis of more than 50 genes associated with solid organ or hematolymphoid neoplasm or disorder, with interrogation for mRNA expression levels


name: Genomic sequence analysis with RNA analysis of more than 50 genes associated with solid organ or hematolymphoid neoplasm or disorder, with interrogation for sequence variants and copy number variants and rearrangement


name: Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants


name: Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants; DNA analysis, microsatellite instability


name: Genomic sequence analysis panel of DNA for microsatellite instability in solid organ abnormal growth of tissue


name: Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants; DNA analysis, copy number variants and microsatellite instability


name: Genomic sequence analysis panel of DNA for microsatellite instability and copy number of variants in solid organ abnormal growth of tissue


name: Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants; DNA analysis or combined DNA and RNA analysis, copy number variants, microsatellite instability, tumor mutation burden, and rearrangements


name: Genomic sequence analysis panel of DNA or combined DNA and RNA for copy number variants, microsatellite instability, tumor mutation burden, and rearrangements in solid organ abnormal growth of tissue


name: Genomic sequence analysis panel with DNA analysis associated with solid organ neoplasm, interrogation for sequence variants, copy number variants, microsatellite instability, tumor mutation burden, and rearrangements


name: Genomic sequence analysis with combined DNA and RNA analysis associated with solid organ neoplasm, with interrogation for sequence variants, copy number variants, microsatellite instability, tumor mutation burden, and rearrangements


name: Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (eg, plasma), interrogation for sequence variants


name: Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (eg, plasma), interrogation for sequence variants; DNA analysis or combined DNA and RNA analysis, copy number variants and rearrangements


name: Genomic sequence analysis of DNA or combined DNA and RNA in plasma for copy number variants and rearrangements in solid organ abnormal growth of tissue


name: Genomic sequence analysis panel with DNA analysis of cell-free nucleic acid associated with solid organ neoplasm, interrogation for sequence variants, copy number variants and rearrangements


name: Genomic sequence analysis panel with combined DNA and RNA analysis of cell-free nucleic acid associated with solid organ neoplasm, interrogation for sequence variants, copy number variants and rearrangements


name: Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (eg, plasma), interrogation for sequence variants; DNA analysis, copy number variants, and microsatellite instability


name: Genomic sequence analysis of DNA in plasma for copy number variants and microsatellite instability in solid organ abnormal growth of tissue


name: Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (eg, plasma), interrogation for sequence variants; DNA analysis or combined DNA and RNA analysis, copy number variants, microsatellite instability, tumor mutation burden, and rearrangements


name: Genomic sequence analysis of DNA or combined DNA and RNA in plasma for copy number variants, microsatellite instability, tumor mutation burden, and rearrangements in solid organ abnormal growth of tissue


name: Genomic sequence analysis panel with DNA analysis of cell-free nucleic acid associated with solid organ neoplasm, interrogation for sequence variants, copy number variants, microsatellite instability, tumor mutation burden, and rearrangements


name: Genomic sequence analysis panel with combined DNA and RNA analysis of cell-free nucleic acid associated with solid organ neoplasm, with interrogation for sequence variants, copy number variants, microsatellite instability, tumor mutation burden, and rearrangements


name: Test for detecting 3 biomarkers associated with risk for liver disease


name: Detection of Hepatitis B surface antigen (HBsAg)


name: Quantitative detection of Hepatitis B surface antigen (HBsAg) by enzyme linked immunoassay (EIA)


name: Quantitative detection of Hepatitis B surface antigen (HBsAg) by enzyme-linked immunosorbent assay (ELISA)


name: Quantitative detection of Hepatitis B surface antigen (HBsAg) by fluorescence immunoassay (FIA)


name: Quantitative detection of Hepatitis B surface antigen (HBsAg) by immunochemiluminometric assay (IMCA)


name: Infectious agent detection by nucleic acid (DNA or RNA); hepatitis D (delta), quantification, including reverse transcription, when performed


name: Detection of hepatitis D (delta) by DNA nucleic acid quantification


name: Detection of hepatitis D (delta) by DNA nucleic acid quantification with reverse transcription


name: Detection of hepatitis D (delta) by RNA nucleic acid quantification


name: Detection of hepatitis D (delta) by RNA nucleic acid quantification with reverse transcription


name: Detection of Orthopox virus nucleic acid by amplified DNA probe technique


name: Targeted genomic sequence analysis panel, non-small cell lung neoplasia, DNA and RNA analysis, 23 genes, interrogation for sequence variants and rearrangements, reported as presence or absence of variants and associated therapy(ies) to consider


name: DNA and RNA targeted sequencing analysis of 1-23 genes associated with non-small cell lung cancer, reported as presence/absence of variants and associated therapies to consider


name: Genomic sequence analysis of 22 genes for detection of abnormalities associated with autosomal dominant congenital thrombocytopenia (low platelet count)


name: Genomic sequence analysis of 22 genes associated with autosomal dominant congenital thrombocytopenia in amniotic fluid


name: Genomic sequence analysis of 22 genes associated with autosomal dominant congenital thrombocytopenia in blood


name: Genomic sequence analysis of 22 genes associated with autosomal dominant congenital thrombocytopenia in buccal swab


name: Genomic sequence analysis of 24 genes for detection of abnormalities associated with congenital neutropenia (low white blood cell count)


name: Genomic sequence analysis of 24 genes associated with congenital neutropenia in amniotic fluid


name: Genomic sequence analysis of 24 genes associated with congenital neutropenia in blood


name: Genomic sequence analysis of 24 genes associated with congenital neutropenia in buccal swab


name: Comprehensive genomic sequence analysis of 60 genes for detection of abnormalities associated with congenital bleeding disorders


name: Comprehensive deletion analysis of PLAU associated with genetic bleeding disorders in amniotic fluid


name: Comprehensive deletion analysis of PLAU associated with genetic bleeding disorders in blood


name: Comprehensive deletion analysis of PLAU associated with genetic bleeding disorders in buccal swab


name: Comprehensive deletion and duplication analysis of PLAU associated with genetic bleeding disorders in amniotic fluid


name: Comprehensive deletion and duplication analysis of PLAU associated with genetic bleeding disorders in blood


name: Comprehensive deletion and duplication analysis of PLAU associated with genetic bleeding disorders in buccal swab


name: Comprehensive duplication analysis of PLAU associated with genetic bleeding disorders in amniotic fluid


name: Comprehensive duplication analysis of PLAU associated with genetic bleeding disorders in blood


name: Comprehensive duplication analysis of PLAU associated with genetic bleeding disorders in buccal swab


name: Comprehensive genomic sequence analysis of 60 genes and duplication/deletion analysis of PLAU associated with genetic bleeding disorders in amniotic fluid


name: Comprehensive genomic sequence analysis of 60 genes and duplication/deletion analysis of PLAU associated with genetic bleeding disorders in blood


name: Comprehensive genomic sequence analysis of 60 genes and duplication/deletion analysis of PLAU associated with genetic bleeding disorders in buccal swab


name: Comprehensive genomic sequence analysis of 60 genes associated with genetic bleeding disorders in amniotic fluid


name: Comprehensive genomic sequence analysis of 60 genes associated with genetic bleeding disorders in blood


name: Comprehensive genomic sequence analysis of 60 genes associated with genetic bleeding disorders in buccal swab


name: Genomic sequence analysis of 62 genes for detection of abnormalities associated with genetic platelet disorders


name: Deletion and duplication analysis of PLAU associated with genetic platelet disorders in amniotic fluid


name: Deletion and duplication analysis of PLAU associated with genetic platelet disorders in blood


name: Deletion and duplication analysis of PLAU associated with genetic platelet disorders in blood, buccal swab, or amniotic fluid


name: Deletion and duplication analysis of PLAU associated with genetic platelet disorders in buccal swab


name: Genomic sequence analysis of 62 genes and deletion analysis of PLAU associated with genetic platelet disorders in amniotic fluid


name: Genomic sequence analysis of 62 genes and deletion analysis of PLAU associated with genetic platelet disorders in blood


name: Genomic sequence analysis of 62 genes and deletion analysis of PLAU associated with genetic platelet disorders in buccal swab


name: Genomic sequence analysis of 62 genes and duplication analysis of PLAU associated with genetic platelet disorders in amniotic fluid


name: Genomic sequence analysis of 62 genes and duplication analysis of PLAU associated with genetic platelet disorders in blood


name: Genomic sequence analysis of 62 genes and duplication analysis of PLAU associated with genetic platelet disorders in buccal swab


name: Genomic sequence analysis of 62 genes and duplication and deletion analysis of PLAU associated with genetic platelet disorders in amniotic fluid


name: Genomic sequence analysis of 62 genes and duplication and deletion analysis of PLAU associated with genetic platelet disorders in blood


name: Genomic sequence analysis of 62 genes and duplication and deletion analysis of PLAU associated with genetic platelet disorders in buccal swab


name: Genomic sequence analysis of 62 genes associated with genetic platelet disorders in amniotic fluid


name: Genomic sequence analysis of 62 genes associated with genetic platelet disorders in blood


name: Genomic sequence analysis of 62 genes associated with genetic platelet disorders in buccal swab


name: Genomic sequence analysis of 40 genes for detection of abnormalities associated with genetic platelet function disorder


name: Deletion analysis of PLAU associated with genetic platelet function disorder in amniotic fluid


name: Deletion analysis of PLAU associated with genetic platelet function disorder in blood


name: Deletion analysis of PLAU associated with genetic platelet function disorder in blood, buccal swab, or amniotic fluid


name: Deletion analysis of PLAU associated with genetic platelet function disorder in buccal swab


name: Deletion and duplication analysis of PLAU associated with genetic platelet function disorder in amniotic fluid


name: Deletion and duplication analysis of PLAU associated with genetic platelet function disorder in blood


name: Deletion and duplication analysis of PLAU associated with genetic platelet function disorder in blood, buccal swab, or amniotic fluid


name: Deletion and duplication analysis of PLAU associated with genetic platelet function disorder in buccal swab


name: Duplication analysis of PLAU associated with genetic platelet function disorder in amniotic fluid


name: Duplication analysis of PLAU associated with genetic platelet function disorder in blood


name: Duplication analysis of PLAU associated with genetic platelet function disorder in blood, buccal swab, or amniotic fluid


name: Duplication analysis of PLAU associated with genetic platelet function disorder in buccal swab


name: Genomic sequence analysis of 40 genes and analysis of PLAU associated with genetic platelet disorders in buccal swab


name: Genomic sequence analysis of 40 genes and deletion analysis of PLAU associated with genetic platelet disorders in amniotic fluid


name: Genomic sequence analysis of 40 genes and deletion analysis of PLAU associated with genetic platelet disorders in blood


name: Genomic sequence analysis of 40 genes and deletion analysis of PLAU associated with genetic platelet disorders in blood, buccal swab, or amniotic fluid


name: Genomic sequence analysis of 40 genes and deletion analysis of PLAU associated with genetic platelet disorders in buccal swab


name: Genomic sequence analysis of 40 genes and deletion and duplication analysis of PLAU associated with genetic platelet disorders in amniotic fluid


name: Genomic sequence analysis of 40 genes and deletion and duplication analysis of PLAU associated with genetic platelet disorders in blood


name: Genomic sequence analysis of 40 genes and deletion and duplication analysis of PLAU associated with genetic platelet disorders in buccal swab


name: Genomic sequence analysis of 40 genes and duplication analysis of PLAU associated with genetic platelet disorders in amniotic fluid


name: Genomic sequence analysis of 40 genes and duplication analysis of PLAU associated with genetic platelet disorders in blood


name: Genomic sequence analysis of 40 genes and duplication analysis of PLAU associated with genetic platelet disorders in blood, buccal swab, or amniotic fluid


name: Genomic sequence analysis of 40 genes associated with genetic platelet function disorder in amniotic fluid


name: Genomic sequence analysis of 40 genes associated with genetic platelet function disorder in blood


name: Genomic sequence analysis of 14 genes for detection of abnormalities associated with genetic thrombosis (excessive clotting)


name: Genomic sequence analysis of 12 genes associated with genetic thrombosis in buccal swab


name: Genomic sequence analysis of 14 genes associated with genetic thrombosis in amniotic fluid


name: Genomic sequence analysis of 14 genes associated with genetic thrombosis in blood


name: Analysis of 3 proteins in plasma specimen, algorithm reported as risk score for obstructive coronary heart disease


name: Evaluation of 17 DNA biomarkers reported as a risk score for cancer recurrence


name: Enzyme immunoassay analysis of beta-amyloid fragments in cerebral spinal fluid to evaluate mild mental impairment


name: Phase separation and immunoassay evaluation of prostate-specific antigen (PSA) in plasma to evaluate risk of prostate cancer


name: Enzyme-linked immunosorbent assay of autoantibodies in plasma to evaluate risk of malignancy in lung cancer


name: Gene-expression profiling--enrichment RNA sequencing of 82 content genes and 10 housekeeping genes reported as one of three molecular subtypes in papillary thyroid cancer


name: Gene-expression profiling via targeted hybrid capture-enrichment RNA sequencing of 82 content genes and 10 housekeeping genes in fine needle aspirate tissue, algorithm reported as one of three molecular subtypes for evaluation of papillary thyroid cancer


name: Gene-expression profiling via targeted hybrid capture-enrichment RNA sequencing of 82 content genes and 10 housekeeping genes in formalin-fixed paraffin embedded (FFPE) tissue, algorithm reported as one of three molecular subtypes for evaluation of papillary thyroid cancer


name: Gene-expression profiling of 5 genes in urine reported as a risk score for having urothelial carcinoma


name: Oncology (hematolymphoid neoplasm), genomic sequence analysis using multiplex (PCR) and next-generation sequencing with algorithm, quantification of dominant clonal sequence(s), reported as presence or absence of minimal residual disease (MRD) with quantitation of disease burden, when appropriate


name: Genomic sequence testing for presence or absence of cancer cells after treatment in leukemia or lymphoma


name: Genomic sequence analysis using multiplex (PCR) and next-generation sequencing with algorithm, quantification of dominant clonal sequence(s), reported as presence or absence of minimal residual disease (MRD) in hematolymphoid neoplasm


name: Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1, and VEGFA) by immunoassays, urine, algorithm reported as a probability of bladder cancer


name: Test for 10 protein biomarkers for bladder cancer


name: Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1, and VEGFA) by immunoassays, urine, algorithm reported as a probability of recurrent bladder cancer


name: Test for 10 protein biomarkers for recurrent bladder cancer


name: Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1, and VEGFA) by immunoassays, urine, diagnostic algorithm reported as a risk score for probability of rapid recurrence of recurrent or persistent cancer following transurethral resection


name: Test for 10 protein biomarkers for rapid recurrent, recurrent, or persistent bladder cancer after bladder surgery to remove a tumor


name: Immunoassay analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1 and VEGFA) in urine, diagnostic algorithm reported as a risk score for probability of rapid recurrence of persistent cancer following transurethral resection


name: Immunoassay analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1 and VEGFA) in urine, diagnostic algorithm reported as a risk score for probability of rapid recurrence of recurrent cancer following transurethral resection


name: Immunoassay analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1 and VEGFA) in urine, diagnostic algorithm reported as a risk score for probability of rapid recurrence of recurrent or persistent cancer following transurethral resection


name: Oncology (colorectal cancer), evaluation for mutations of APC, BRAF, CTNNB1, KRAS, NRAS, PIK3CA, SMAD4, and TP53, and methylation markers (MYO1G, KCNQ5, C9ORF50, FLI1, CLIP4, ZNF132, and TWIST1), multiplex quantitative polymerase chain reaction (qPCR), circulating cell-free DNA (cfDNA), plasma, report of risk score for advanced adenoma or colorectal cancer


name: Multiplex quantitative polymerase chain reaction (qPCR) evaluation for mutations of APC, BRAF, CTNNB1, KRAS, NRAS, PIK3CA, SMAD4, and TP53, and methylation markers (MYO1G, KCNQ5, C9ORF50, FLI1, CLIP4, ZNF132 and TWIST1) in plasma circulating cell-free DNA (cfDNA), reported as a risk score for advanced adenoma


name: Multiplex quantitative polymerase chain reaction (qPCR) evaluation for mutations of APC, BRAF, CTNNB1, KRAS, NRAS, PIK3CA, SMAD4, and TP53, and methylation markers (MYO1G, KCNQ5, C9ORF50, FLI1, CLIP4, ZNF132 and TWIST1) in plasma circulating cell-free DNA (cfDNA), reported as a risk score for colorectal cancer


name: Infectious agent detection by nucleic acid (DNA and RNA), gastrointestinal pathogens, 31 bacterial, viral, and parasitic organisms and identification of 21 associated antibiotic-resistance genes, multiplex amplified probe technique


name: Test for 31 stomach and intestinal pathogens and identification of 21 antibiotic resistant genes


name: Identification of 31 bacterial, viral, and parasitic gastrointestinal pathogens and identification of 21 associated antibiotic-resistance genes by multiplex DNA amplified probe technique


name: Identification of 31 bacterial, viral, and parasitic gastrointestinal pathogens and identification of 21 associated antibiotic-resistance genes by multiplex DNA and RNA amplified probe technique


name: Identification of 31 bacterial, viral, and parasitic gastrointestinal pathogens and identification of 21 associated antibiotic-resistance genes by multiplex RNA amplified probe technique


name: Infectious agent detection by nucleic acid (DNA and RNA), surgical wound pathogens, 34 microorganisms and identification of 21 associated antibiotic-resistance genes, multiplex amplified probe technique, wound swab


name: Test for 34 surgical wound microorganisms and identification of 21 antibiotic resistant genes


name: Identification of 34 microorganisms and identification of 21 associated antibiotic-resistance genes from swab of surgical wound by multiplex DNA amplified probe technique


name: Identification of 34 microorganisms and identification of 21 associated antibiotic-resistance genes from swab of surgical wound by multiplex DNA and RNA amplified probe technique


name: Identification of 34 microorganisms and identification of 21 associated antibiotic-resistance genes from swab of surgical wound by multiplex RNA amplified probe technique


name: Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogen, semiquantitative identification, DNA from 16 bacterial organisms and 1 fungal organism, multiplex amplified probe technique via quantitative polymerase chain reaction (qPCR), urine


name: Test for 16 genitourinary bacterial organisms and 1 genitourinary fungal organism


name: Identification of DNA from 16 bacterial organisms and 1 fungal organism in urine by multiplex DNA amplified probe technique via quantitative polymerase chain reaction (qPCR)


name: Identification of DNA from 16 bacterial organisms and 1 fungal organism in urine by multiplex DNA or RNA amplified probe technique via quantitative polymerase chain reaction (qPCR)


name: Identification of DNA from 16 bacterial organisms and 1 fungal organism in urine by multiplex RNA amplified probe technique via quantitative polymerase chain reaction (qPCR)


name: Infectious disease (genitourinary pathogens), antibiotic-resistance gene detection, multiplex amplified probe technique, urine, reported as an antimicrobial stewardship risk score


name: Test for genitourinary pathogen antibiotic-resistance genes


name: Infectious agent detection by nucleic acid (DNA and RNA), respiratory tract infection, 17 bacteria, 8 fungus, 13 virus, and 16 antibiotic-resistance genes, multiplex amplified probe technique, upper or lower respiratory specimen


name: Test for 17 bacteria, 8 fungus, 13 virus, and 16 antibiotic-resistance genes associated with respiratory infection


name: Identification of 17 bacteria, 8 fungus, 13 virus, and 16 antibiotic-resistance genes in lower respiratory specimen by DNA and RNA multiplex amplified probe technique


name: Identification of 17 bacteria, 8 fungus, 13 virus, and 16 antibiotic-resistance genes in lower respiratory specimen by DNA multiplex amplified probe technique


name: Identification of 17 bacteria, 8 fungus, 13 virus, and 16 antibiotic-resistance genes in lower respiratory specimen by RNA multiplex amplified probe technique


name: Identification of 17 bacteria, 8 fungus, 13 virus, and 16 antibiotic-resistance genes in upper or lower respiratory specimen by DNA multiplex amplified probe technique


name: Identification of 17 bacteria, 8 fungus, 13 virus, and 16 antibiotic-resistance genes in upper or lower respiratory specimen by RNA multiplex amplified probe technique


name: Identification of 17 bacteria, 8 fungus, 13 virus, and 16 antibiotic-resistance genes in upper respiratory specimen by DNA and RNA multiplex amplified probe technique


name: Identification of 17 bacteria, 8 fungus, 13 virus, and 16 antibiotic-resistance genes in upper respiratory specimen by DNA multiplex amplified probe technique


name: Identification of 17 bacteria, 8 fungus, 13 virus, and 16 antibiotic-resistance genes in upper respiratory specimen by RNA multiplex amplified probe technique


name: Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogens, identification of 21 bacterial and fungal organisms and identification of 21 associated antibiotic-resistance genes, multiplex amplified probe technique, urine


name: Test for 21 bacterial and fungal genitourinary pathogens and identification of 21 associated antibiotic-resistance genes


name: Identification of 21 bacterial and fungal genitourinary pathogens and identification of 21 associated antibiotic resistance genes in urine by DNA multiplex amplified probe technique


name: Identification of 21 bacterial and fungal genitourinary pathogens and identification of 21 associated antibiotic resistance genes in urine by RNA multiplex amplified probe technique


name: Oncology (ovarian), biochemical assays of 7 proteins (follicle stimulating hormone, human epididymis protein 4, apolipoprotein A-1, transferrin, beta-2 macroglobulin, prealbumin [ie, transthyretin], and cancer antigen 125), algorithm reported as ovarian cancer risk score


name: Test for proteins to determine risk for ovarian cancer


name: Oncology (prostate cancer), image analysis of at least 128 histologic features and clinical factors, prognostic algorithm determining the risk of distant metastases, and prostate cancer-specific mortality, includes predictive algorithm to androgen deprivation-therapy response, if appropriate


name: Test to determine potential risk of prostate cancer spread and mortality


name: Image analysis of at least 128 histologic features and clinical factors, prognostic algorithm determining the risk of distant metastases, and prostate cancer-specific mortality


name: Cardiovascular disease, quantification of advanced serum or plasma lipoprotein profile, by nuclear magnetic resonance (NMR) spectrometry with report of a lipoprotein profile (including 23 variables)


name: Test of lipoprotein profile in cardiovascular disease


name: RFC1 (replication factor C subunit 1), repeat expansion variant analysis by traditional and repeat-primed PCR, blood, saliva, or buccal swab


name: Test for RFC1 (replication factor C subunit 1) in neurological conditions


name: Repeat expansion variant analysis of replication factor C subunit 1 (RFC1 by traditional and repeat-primed PCR in blood


name: Repeat expansion variant analysis of replication factor C subunit 1 (RFC1 by traditional and repeat-primed PCR in buccal swab


name: Repeat expansion variant analysis of replication factor C subunit 1 (RFC1 by traditional and repeat-primed PCR in saliva


name: Targeted genomic sequence analysis panel, solid organ neoplasm, DNA (523 genes) and RNA (55 genes) by next-generation sequencing, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability, and tumor mutational burden


name: Drug metabolism (adverse drug reactions and drug response), targeted sequence analysis, 20 gene variants and CYP2D6 deletion or duplication analysis with reported genotype and phenotype


name: Test for adverse drug reactions and drug response


name: Targeted sequence analysis of 20 gene variants and CYP2D6 by deletion analysis with reported genotype and phenotype for evaluation of drug metabolism


name: Targeted sequence analysis of 20 gene variants and CYP2D6 by duplication analysis with reported genotype and phenotype for evaluation of drug metabolism


name: Maple syrup urine disease monitoring by patient-collected blood card sample, quantitative measurement of allo-isoleucine, leucine, isoleucine, and valine, liquid chromatography with tandem mass spectrometry (LC-MS/MS)


name: Test for monitoring maple syrup urine disease


name: Hyperphenylalaninemia monitoring by patient-collected blood card sample, quantitative measurement of phenylalanine and tyrosine, liquid chromatography with tandem mass spectrometry (LC-MS/MS)


name: Test for monitoring hyperphenylalaninemia


name: Tyrosinemia type I monitoring by patient-collected blood card sample, quantitative measurement of tyrosine, phenylalanine, methionine, succinylacetone, nitisinone, liquid chromatography with tandem mass spectrometry (LC-MS/MS)


name: Nephrology (chronic kidney disease), carboxymethyllysine, methylglyoxal hydroimidazolone, and carboxyethyl lysine by liquid chromatography with tandem mass spectrometry (LC-MS/MS) and HbA1c and estimated glomerular filtration rate (GFR), with risk score reported for predictive progression to high-stage kidney disease


name: Test for predictive risk of progression of high-stage kidney disease


name: Nephrology (chronic kidney disease), apolipoprotein A4 (ApoA4), CD5 antigen-like (CD5L), and insulin-like growth factor binding protein 3 (IGFBP3) by enzyme-linked immunoassay (ELISA), plasma, algorithm combining results with HDL, estimated glomerular filtration rate (GFR) and clinical data reported as a risk score for developing diabetic kidney disease


name: Testing for risk of developing diabetic kidney disease


name: Oncology (melanoma), autophagy and beclin 1 regulator 1 (AMBRA1) and loricrin (AMLo) by immunohistochemistry, formalin-fixed paraffin-embedded (FFPE) tissue, report for risk of progression


name: Tissue evaluation for proteins to report risk of skin cancer progression


name: Oncology (non-small cell lung cancer), next-generation sequencing with identification of single nucleotide variants, copy number variants, insertions and deletions, and structural variants in 37 cancer-related genes, plasma, with report for alteration detection


name: Next-generation sequencing in plasma of 37 cancer-related genes, with report for alteration detection in non-small cell lung cancer


name: Pediatric febrile illness (Kawasaki disease [KD]), interferon alpha-inducible protein 27 (IFI27) and mast cell-expressed membrane protein 1 (MCEMP1), RNA, using quantitative reverse transcription polymerase chain reaction (RT-qPCR), blood, reported as a risk score for KD


name: Reverse transcription polymerase chain reaction (RT-qPCR) testing of blood for proteins, reported as a risk score for Kawasaki disease


name: Obstetrics (preeclampsia), kinase insert domain receptor (KDR), Endoglin (ENG), and retinol-binding protein 4 (RBP4), by immunoassay, serum, algorithm reported as a risk score


name: Immunoassay of serum for proteins, reported as a risk score for preeclampsia


name: Oncology (solid tumor), DNA and RNA by next-generation sequencing, utilizing formalin-fixed paraffin-embedded (FFPE) tissue, 437 genes, interpretive report for single nucleotide variants, splice-site variants, insertions/deletions, copy number alterations, gene fusions, tumor mutational burden, and microsatellite instability, with algorithm quantifying immunotherapy response score


name: DNA and RNA next-generation sequencing of tissue for 437 genes with algorithm quantifying immunotherapy response score


name: Drug metabolism (depression, anxiety, attention deficit hyperactivity disorder [ADHD]), gene-drug interactions, variant analysis of 16 genes, including deletion/duplication analysis of CYP2D6, reported as impact of gene-drug interaction for each drug


name: Evaluation of gene-drug interactions for 16 genes reported as impact of gene-drug interaction for each drug for depression, anxiety, attention deficit disorder


name: Variant analysis of 16 genes including deletion analysis of CYP2D26 reported as impact of gene-drug interaction for each drug in anxiety


name: Variant analysis of 16 genes including deletion analysis of CYP2D26 reported as impact of gene-drug interaction for each drug in attention deficit hyperactivity disorder [ADHD]


name: Variant analysis of 16 genes including deletion analysis of CYP2D26 reported as impact of gene-drug interaction for each drug in depression


name: Variant analysis of 16 genes including deletion analysis of CYP2D26 reported as impact of gene-drug interaction for each drug in depression, anxiety, attention deficit hyperactivity disorder [ADHD]


name: Variant analysis of 16 genes including deletion and duplication analysis of CYP2D26 reported as impact of gene-drug interaction for each drug in anxiety


name: Variant analysis of 16 genes including deletion and duplication analysis of CYP2D26 reported as impact of gene-drug interaction for each drug in attention deficit hyperactivity disorder [ADHD]


name: Variant analysis of 16 genes including deletion and duplication analysis of CYP2D26 reported as impact of gene-drug interaction for each drug in depression


name: Variant analysis of 16 genes including duplication analysis of CYP2D26 reported as impact of gene-drug interaction for each drug in anxiety


name: Variant analysis of 16 genes including duplication analysis of CYP2D26 reported as impact of gene-drug interaction for each drug in attention deficit hyperactivity disorder [ADHD]


name: Variant analysis of 16 genes including duplication analysis of CYP2D26 reported as impact of gene-drug interaction for each drug in depression


name: Variant analysis of 16 genes including duplication analysis of CYP2D26 reported as impact of gene-drug interaction for each drug in depression, anxiety, attention deficit hyperactivity disorder [ADHD]


name: Neurology (eg, Parkinson disease, dementia with Lewy bodies), cerebrospinal fluid (CSF), detection of misfolded α-synuclein protein by seed amplification assay, qualitative


name: Detection of protein by seed amplification assay for neurological disorders


name: Detection of misfolded α-synuclein protein by qualitative seed amplification assay in cerebrospinal fluid (CSF) in Parkinson disease


name: Detection of misfolded α-synuclein protein by qualitative seed amplification assay in cerebrospinal fluid (CSF) in dementia with Lewy bodies


name: Perfluoroalkyl substances (PFAS) (eg, perfluorooctanoic acid, perfluorooctane sulfonic acid), 16 PFAS compounds by liquid chromatography with tandem mass spectrometry (LC-MS/MS), plasma or serum, quantitative


name: Testing of plasma or serum for 16 perfluoroalkyl substances (PFAS) compounds


name: Evaluation of 16 perfluoroalkyl substances (PFAS) compounds by liquid chromatography with tandem mass spectrometry (LC-MS/MS) in plasma


name: Evaluation of 16 perfluoroalkyl substances (PFAS) compounds by liquid chromatography with tandem mass spectrometry (LC-MS/MS) in plasma or serum


name: Evaluation of 16 perfluoroalkyl substances (PFAS) compounds by liquid chromatography with tandem mass spectrometry (LC-MS/MS) in serum


name: Evaluation of perfluorooctane sulfonic acid by liquid chromatography with tandem mass spectrometry (LC-MS/MS) in plasma


name: Evaluation of perfluorooctane sulfonic acid by liquid chromatography with tandem mass spectrometry (LC-MS/MS) in plasma or serum


name: Evaluation of perfluorooctane sulfonic acid by liquid chromatography with tandem mass spectrometry (LC-MS/MS) in serum


name: Evaluation of perfluorooctanoic acid by liquid chromatography with tandem mass spectrometry (LC-MS/MS) in plasma


name: Evaluation of perfluorooctanoic acid by liquid chromatography with tandem mass spectrometry (LC-MS/MS) in plasma or serum


name: Evaluation of perfluorooctanoic acid by liquid chromatography with tandem mass spectrometry (LC-MS/MS) in serum


name: Oncology (lung), multi-omics (microbial DNA by shotgun next-generation sequencing and carcinoembryonic antigen and osteopontin by immunoassay), plasma, algorithm reported as malignancy risk for lung nodules in early-stage disease


name: Multi-omics testing of plasma reported as risk of malignancy for lung nodules in early-stage lung cancer


name: Obstetrics (pre-implantation genetic testing), evaluation of 300000 DNA single-nucleotide polymorphisms (SNPs) by microarray, embryonic tissue, algorithm reported as a probability for single-gene germline conditions


name: Gastroenterology (Barrett's esophagus), P16, RUNX3, HPP1, and FBN1 DNA methylation analysis using PCR, formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as risk score for progression to high-grade dysplasia or cancer


name: DNA methylation analysis using polymerase chain reaction testing of tissue for genes specific to Barrett esophagus, reported as a risk score for progression to high grade dysplasia or cancer


name: Neurology (cerebral folate deficiency), serum, detection of anti-human folate receptor IgG-binding antibody and blocking autoantibodies by enzyme-linked immunoassay (ELISA), qualitative, and blocking autoantibodies, using a functional blocking assay for IgG or IgM, quantitative, reported as positive or not detected


name: Enzyme-linked assay detection in serum of IgG-binding antibody and blocking autoantibodies, using a functional blocking assay for IgG or IgM reported as positive or not detected in cerebral folate deficiency


name: Enzyme-linked immunoassay (ELISA) for detection of anti-human folate receptor IgG-binding antibody and blocking autoantibodies in serum using a functional blocking assay for IgG or IgM, quantitative, reported as positive or not detected in cerebral folate deficiency


name: Obstetrics (expanded carrier screening), 145 genes by next-generation sequencing, fragment analysis and multiplex ligation-dependent probe amplification, DNA, reported as carrier positive or negative


name: Next-generation sequencing of DNA for 145 genes reported as carrier positive or negative in expanded carrier screening


name: Cardiology (coronary heart disease [CHD]), 9 genes (12 variants), targeted variant genotyping, blood, saliva, or buccal swab, algorithm reported as a genetic risk score for a coronary event


name: Targeted variant genotyping using blood, saliva, or buccal swab of 9 genes for coronary heart disease reported as a risk score for a coronary event


name: Targeted variant genotyping of 9 genes (12 variants) in blood, algorithm reported as a genetic risk score for a coronary event in coronary heart disease [CAD]


name: Targeted variant genotyping of 9 genes (12 variants) in buccal swab, algorithm reported as a genetic risk score for a coronary event in coronary heart disease [CAD]


name: Targeted variant genotyping of 9 genes (12 variants) in saliva, algorithm reported as a genetic risk score for a coronary event in coronary heart disease [CAD]


name: Infectious agent (sexually transmitted infection), Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium, multiplex amplified probe technique, vaginal, endocervical, or male urine, each pathogen reported as detected or not detected


name: Detection of organisms causing sexually transmitted infection by multiplex amplified probe technique


name: Detection of Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium in endocervical specimen using multiplex amplified probe technique, each pathogen reported as detected or not detected


name: Detection of Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium in male urine specimen using multiplex amplified probe technique, each pathogen reported as detected or not detected


name: Detection of Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium in vaginal specimen using multiplex amplified probe technique, each pathogen reported as detected or not detected


name: Oncology (prostate), mRNA, gene expression profiling of 18 genes, first-catch post-digital rectal examination urine (or processed first-catch urine), algorithm reported as percentage of likelihood of detecting clinically significant prostate cancer


name: mRNA expression profiling of 18 genes to detect potential risk of prostate cancer


name: Evaluation of 18 genes by mRNA gene expression profiling in first-catch post-digital rectal examination urine, algorithm reported as percentage of likelihood of detecting clinically significant prostate cancer


name: Evaluation of 18 genes by mRNA gene expression profiling in processed first-catch urine, algorithm reported as percentage of likelihood of detecting clinically significant prostate cancer


name: Oncology (breast), semiquantitative measurement of thymidine kinase activity by immunoassay, serum, results reported as risk of disease progression


name: Analysis of serum using immunoassay technique for thymidine kinase activity in breast cancer


name: Oncology (pancreatic), 59 methylation haplotype block markers, next-generation sequencing, plasma, reported as cancer signal detected or not detected


name: Sequencing of methylation haplotype block markers in plasma in pancreatic cancer


name: Oncology (lung), flow cytometry, sputum, 5 markers (meso-tetra [4-carboxyphenyl] porphyrin [TCPP], CD206, CD66b, CD3, CD19), algorithm reported as likelihood of lung cancer


name: Flow cytometry detection of 5 markers in sputum to evaluate potential for lung cancer


name: Nephrology (diabetic chronic kidney disease [CKD]), multiplex electrochemiluminescent immunoassay (ECLIA) of soluble tumor necrosis factor receptor 1 (sTNFR1), soluble tumor necrosis receptor 2 (sTNFR2), and kidney injury molecule 1 (KIM-1) combined with clinical data, plasma, algorithm reported as risk for progressive decline in kidney function


name: Measurement of soluble tumor necrosis factor receptor 1 (sTNFR1), soluble tumor necrosis receptor 2 (sTNFR2), and kidney injury molecule 1 (KIM-1) to evaluate risk of progressive decline in kidney function in diabetic chronic kidney disease


name: Infectious agent antigen detection by bulk acoustic wave biosensor immunoassay, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])


name: Oncology (solid tumor), DNA (80 genes) and RNA (36 genes), by next-generation sequencing from plasma, including single nucleotide variants, insertions/deletions, copy number alterations, microsatellite instability, and fusions, report showing identified mutations with clinical actionability


name: Next-generation sequencing of DNA (80 genes) and RNA (39 genes) in plasma showing mutations and clinical actionability in solid tumor cancers


name: Oncology (pancreatic), DNA, whole genome sequencing with 5-hydroxymethylcytosine enrichment, whole blood or plasma, algorithm reported as cancer detected or not detected


name: Whole genome sequencing of DNA in whole blood or plasma to detect pancreatic cancer


name: Whole genome DNA sequencing with hydroxymethylcytosine enrichment in plasma, algorithm reported as cancer detected or not detected in pancreatic cancer


name: Whole genome DNA sequencing with hydroxymethylcytosine enrichment in whole blood or plasma, algorithm reported as cancer detected or not detected in pancreatic cancer


name: Whole genome DNA sequencing with hydroxymethylcytosine enrichment in whole blood, algorithm reported as cancer detected or not detected in pancreatic cancer


name: Genomic analysis of 15 genes to evaluate for psychiatric disorders


name: Genomic analysis panel with variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6 in anxiety


name: Genomic analysis panel with variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6 in attention deficit hyperactivity disorder (ADHD)


name: Genomic analysis panel with variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6 in depression


name: Genomic analysis panel with variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6 in depression, anxiety, attention deficit hyperactivity disorder (ADHD)


name: Beta amyloid, Aβ42/40 ratio, immunoprecipitation with quantitation by liquid chromatography with tandem mass spectrometry (LC-MS/MS) and qualitative ApoE isoform-specific proteotyping, plasma combined with age, algorithm reported as presence or absence of brain amyloid pathology


name: Measurement of Aβ42/40 ratio in plasma to evaluation for brain amyloid pathology


name: Oncology (hematolymphoid neoplasm), optical genome mapping for copy number alterations, aneuploidy, and balanced/complex structural rearrangements, DNA from blood or bone marrow, report of clinically significant alterations


name: Optical genome mapping of DNA in blood or bone marrow for changes in copy number alterations, aneuploidy, and balanced/complex structural rearrangements in blood and lymphatic system abnormal tissue


name: Oncology (lung), augmentative algorithmic analysis of digitized whole slide imaging for 8 genes (ALK, BRAF, EGFR, ERBB2, MET, NTRK1-3, RET, ROS1), and KRAS G12C and PD-L1, if performed, formalin-fixed paraffin-embedded (FFPE) tissue, reported as positive or negative for each biomarker


name: Whole slide imaging analysis for 8 genes for evaluation of lung cancer


name: Evaluation for 8 genes (ALK, BRAF, EGFR, ERBB2, MET, NTRK1-3, RET, ROS1) and nd KRAS G12C and PD-L1 if performed, in formalin-fixed paraffin-embedded (FFPE) tissue by whole slide imaging analysis, reported as positive or negative for each biomarker in lung cancer


name: Cardiovascular disease (acute coronary syndrome [ACS]), IL-16, FAS, FASLigand, HGF, CTACK, EOTAXIN, and MCP-3 by immunoassay combined with age, sex, family history, and personal history of diabetes, blood, algorithm reported as a 5-year (deleted risk) score for ACS


name: Test of biomarkers in blood combined with patient factors to determine a 5-year risk score for acute coronary syndrome


name: Detection of DNA of 20 organisms in urine


name: Identification of 20 bacterial and fungal genitourinary organisms in urine by multiplex amplified DNA probe technique


name: Rare diseases (constitutional/heritable disorders), whole mitochondrial genome sequence with heteroplasmy detection and deletion analysis, nuclear-encoded mitochondrial gene analysis of 335 nuclear genes, including sequence changes, deletions, insertions, and copy number variants analysis, blood or saliva, identification and categorization of mitochondrial disorder-associated genetic variants


name: Whole genome sequence analysis of 335 nuclear genes in blood or saliva for detection of abnormalities associated with rare constitutional/heritable diseases


name: Evaluation of 355 nuclear genes in blood by whole mitochondrial genome sequence with heteroplasmy detection and deletion analysis, including sequence changes, deletions, insertions, and copy number variants analysis, identification and categorization of mitochondrial disorder-associated genetic variants


name: Evaluation of 355 nuclear genes in blood or saliva by whole mitochondrial genome sequence with heteroplasmy detection and deletion analysis, including sequence changes, deletions, insertions, and copy number variants analysis, identification and categorization of mitochondrial disorder-associated genetic variants


name: Evaluation of 355 nuclear genes in saliva by whole mitochondrial genome sequence with heteroplasmy detection and deletion analysis, including sequence changes, deletions, insertions, and copy number variants analysis, identification and categorization of mitochondrial disorder-associated genetic variants


name: Oncology (breast), augmentative algorithmic analysis of digitized whole slide imaging of 8 histologic and immunohistochemical features, reported as a recurrence score


name: Image analysis of breast cancer cell specimen with autonomous assessment


name: Evaluation of 8 histologic and immunohistochemical features by image analysis and autonomous assessment, reported as a recurrence score for breast cancer


name: Neuropsychiatry (eg, depression, anxiety), genomic sequence analysis panel, variant analysis of 13 genes, saliva or buccal swab, report of each gene phenotype


name: Genomic sequence analysis of 13 genes in saliva for evolution of psychiatric disorders


name: Genomic sequence analysis panel of 13 genes in buccal swab, with report of each gene phenotype in anxiety


name: Genomic sequence analysis panel of 13 genes in buccal swab, with report of each gene phenotype in depression


name: Genomic sequence analysis panel of 13 genes in buccal swab, with report of each gene phenotype in depression, anxiety


name: Genomic sequence analysis panel of 13 genes in saliva or buccal swab, with report of each gene phenotype in anxiety


name: Genomic sequence analysis panel of 13 genes in saliva or buccal swab, with report of each gene phenotype in depression


name: Genomic sequence analysis panel of 13 genes in saliva or buccal swab, with report of each gene phenotype in depression, anxiety


name: Genomic sequence analysis panel of 13 genes in saliva, with report of each gene phenotype in anxiety


name: Genomic sequence analysis panel of 13 genes in saliva, with report of each gene phenotype in depression


name: Genomic sequence analysis panel of 13 genes in saliva, with report of each gene phenotype in depression, anxiety


name: Respiratory syncytial virus, monoclonal antibody, seasonal dose


name: Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use


name: Respiratory syncytial virus antibody, 0.5 mL dosage for injection into muscle


name: Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for intramuscular use


name: Respiratory syncytial virus antibody, 1.0 mL dosage for injection into muscle


name: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, single dose


name: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use


name: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use


name: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use


name: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use


name: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use


name: Chikungunya virus vaccine, live attenuated, for intramuscular use


name: Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use


name: Respiratory syncytial virus vaccine, mRNA lipid nanoparticles, for intramuscular use


name: Respiratory syncytial virus vaccine mRNA lipid nanoparticles


name: Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y- tetanus toxoid carrier, and Men B-FHbp, for intramuscular use


name: Meningococcal conjugate vaccine serogroups A, C, W, Y, B-FHbp, pentavalent, tetanus toxoid carrier


name: Diagnostic analysis, programming, and verification of an auditory osseointegrated sound processor, any type


name: Diagnostic analysis, programming, and verification of an auditory osseointegrated sound processor, any type; first 60 minutes


name: Analysis, programming, and verification of sound processor for bone-anchored inner ear implant, first hour


name: Diagnostic analysis, programming, and verification of an auditory osseointegrated sound processor, any type; each additional 15 minutes (List separately in addition to code for primary procedure)


name: Analysis, programming, and verification of sound processor for bone-anchored inner ear implant, each additional 15 minutes


name: Therapy activation of implanted phrenic nerve stimulator system, including all interrogation and programming


name: Activation of implanted phrenic nerve stimulator


name: Interrogation and programming (minimum one parameter) of implanted phrenic nerve stimulator system


name: Interrogation and programming of implanted phrenic nerve stimulator system during polysomnography


name: Evaluation and programming of implanted phrenic nerve stimulator system during sleep study


name: Interrogation without programming of implanted phrenic nerve stimulator system


name: Interrogation of implanted phrenic nerve stimulator system


name: venography for congenital heart defect, including catheter placement, radiological supervision, interpretation


name: Venography for congenital heart defect(s), including catheter placement, and radiological supervision and interpretation; anomalous or persistent superior vena cava when it exists as a second contralateral superior vena cava, with native drainage to heart (List separately in addition to code for primary procedure)


name: Review by radiologist of vein imaging for congenital heart defect of superior vena cava


name: Venography for congenital heart defect(s), including catheter placement, and radiological supervision and interpretation; azygos/hemiazygos venous system (List separately in addition to code for primary procedure)


name: Review by radiologist of vein imaging for congenital heart defect of the azygos/hemiazygos venous system


name: Venography for congenital heart defect(s), including catheter placement, and radiological supervision and interpretation; coronary sinus (List separately in addition to code for primary procedure)


name: Review by radiologist of vein imaging for congenital heart defect of coronary sinus


name: Venography for congenital heart defect(s), including catheter placement, and radiological supervision and interpretation; venovenous collaterals originating at or above the heart (eg, from innominate vein) (List separately in addition to code for primary procedure)


name: Review by radiologist of vein imaging for congenital heart defect of venovenous collaterals above the heart


name: Venography for congenital heart defect(s), including catheter placement, and radiological supervision and interpretation for innominate vein


name: Venography for congenital heart defect(s), including catheter placement, and radiological supervision and interpretation; venovenous collaterals originating below the heart (eg, from the inferior vena cava) (List separately in addition to code for primary procedure)


name: Review by radiologist of vein imaging for congenital heart defect of venovenous collaterals below the heart


name: Venography for congenital heart defect(s), including catheter placement, and radiological supervision and interpretation for venovenous collaterals originating from the inferior vena cava


name: Chemotherapy administration into the peritoneal cavity via implanted port


name: Intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) procedure, including separate incision(s) and closure, when performed


name: Intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) procedure, including separate incision(s) and closure, when performed; first 60 minutes (List separately in addition to code for primary procedure)


name: Intraoperative heated intraperitoneal chemotherapy, first 60 minutes


name: Intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) procedure, first 60 minutes


name: Intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) procedure, including separate incision(s) and closure, first 60 minutes


name: Intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) procedure, including separate incision(s) and closure, when performed; each additional 30 minutes (List separately in addition to code for primary procedure)


name: Intraoperative heated intraperitoneal chemotherapy, each additional 30 minutes


name: Intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) procedure, each additional 30 minutes


name: Intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) procedure, including separate incision(s) and closure, each additional 30 minutes


name: Application of a modality to 1 or more areas; low-level laser therapy (ie, nonthermal and non-ablative) for post-operative pain reduction


name: Low-level laser therapy application for pain management after surgery


name: Caregiver Training Without the Patient Present


name: Caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community (eg, activities of daily living [ADLs], instrumental ADLs [iADLs], transfers, mobility, communication, swallowing, feeding, problem solving, safety practices) (without the patient present), face to face


name: Caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community (eg, activities of daily living [ADLs], instrumental ADLs [iADLs], transfers, mobility, communication, swallowing, feeding, problem solving, safety practices) (without the patient present), face to face; initial 30 minutes


name: Caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community, initial 30 minutes


name: Caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community including activities of daily living [ADLs] and instrumental ADLs [iADLs], without the patient present, face to face; initial 30 minutes


name: Caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community including activities of daily living [ADLs], instrumental ADLs [iADLs], and transfers, without the patient present, face to face; initial 30 minutes


name: Caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community including activities of daily living [ADLs], instrumental ADLs [iADLs], transfers, and mobility, without the patient present, face to face; initial 30 minutes


name: Caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community including activities of daily living [ADLs], instrumental ADLs [iADLs], transfers, mobility, and communication, without the patient present, face to face; initial 30 minutes


name: Caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community including activities of daily living [ADLs], instrumental ADLs [iADLs], transfers, mobility, communication, and swallowing, without the patient present, face to face; initial 30 minutes


name: Caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community including activities of daily living [ADLs], instrumental ADLs [iADLs], transfers, mobility, communication, swallowing, and feeding, without the patient present, face to face; initial 30 minutes


name: Caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community including activities of daily living [ADLs], instrumental ADLs [iADLs], transfers, mobility, communication, swallowing, feeding, and problem solving, without the patient present, face to face; initial 30 minutes


name: Caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community including activities of daily living [ADLs], instrumental ADLs [iADLs], transfers, mobility, communication, swallowing, feeding, problem solving, safety practices, without the patient present, face to face; initial 30 minutes


name: Caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community including activities of daily living [ADLs], without the patient present, face to face; initial 30 minutes


name: Caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community (eg, activities of daily living [ADLs], instrumental ADLs [iADLs], transfers, mobility, communication, swallowing, feeding, problem solving, safety practices) (without the patient present), face to face; each additional 15 minutes (List separately in addition to code for primary service)


name: Caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community, each additional 15 minutes


name: Caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community including activities of daily living [ADLs] and instrumental ADLs [iADLs], without the patient present, face to face; each additional 15 minutes


name: Caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community including activities of daily living [ADLs], instrumental ADLs [iADLs], and transfers, without the patient present, face to face; each additional 15 minutes


name: Caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community including activities of daily living [ADLs], instrumental ADLs [iADLs], transfers, and mobility, without the patient present, face to face; each additional 15 minutes


name: Caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community including activities of daily living [ADLs], instrumental ADLs [iADLs], transfers, mobility, and communication, without the patient present, face to face; each additional 15 minutes


name: Caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community including activities of daily living [ADLs], instrumental ADLs [iADLs], transfers, mobility, communication, and swallowing, without the patient present, face to face; each additional 15 minutes


name: Caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community including activities of daily living [ADLs], instrumental ADLs [iADLs], transfers, mobility, communication, swallowing, and feeding, without the patient present, face to face; each additional 15 minutes


name: Caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community including activities of daily living [ADLs], instrumental ADLs [iADLs], transfers, mobility, communication, swallowing, feeding, and problem solving, without the patient present, face to face; each additional 15 minutes


name: Caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community including activities of daily living [ADLs], instrumental ADLs [iADLs], transfers, mobility, communication, swallowing, feeding, problem solving, safety practices, without the patient present, face to face; each additional 15 minutes


name: Caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community including activities of daily living [ADLs], without the patient present, face to face; each additional 15 minutes


name: Group caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community (eg, activities of daily living [ADLs], instrumental ADLs [iADLs], transfers, mobility, communication, swallowing, feeding, problem solving, safety practices) (without the patient present), face to face with multiple sets of caregivers


name: Group caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community


name: Group caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community including activities of daily living [ADLs] and instrumental ADLs [iADLs], without the patient present, face to face with multiple sets of caregivers


name: Group caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community including activities of daily living [ADLs], instrumental ADLs [iADLs], and transfers, without the patient present, face to face with multiple sets of caregivers


name: Group caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community including activities of daily living [ADLs], instrumental ADLs [iADLs], transfers, and mobility, without the patient present, face to face with multiple sets of caregivers


name: Group caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community including activities of daily living [ADLs], instrumental ADLs [iADLs], transfers, mobility, and communication, without the patient present, face to face with multiple sets of caregivers


name: Group caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community including activities of daily living [ADLs], instrumental ADLs [iADLs], transfers, mobility, communication, and swallowing, without the patient present, face to face with multiple sets of caregivers


name: Group caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community including activities of daily living [ADLs], instrumental ADLs [iADLs], transfers, mobility, communication, swallowing, and feeding, without the patient present, face to face with multiple sets of caregivers


name: Group caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community including activities of daily living [ADLs], instrumental ADLs [iADLs], transfers, mobility, communication, swallowing, feeding, and problem solving, without the patient present, face to face with multiple sets of caregivers


name: Group caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community including activities of daily living [ADLs], instrumental ADLs [iADLs], transfers, mobility, communication, swallowing, feeding, problem solving, and safety practices, without the patient present, face to face with multiple sets of caregivers


name: Group caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community including activities of daily living [ADLs], without the patient present, face to face with multiple sets of caregivers


name: Noncontact near-infrared spectroscopy (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation), other than for screening for peripheral arterial disease, image acquisition, interpretation, and report


name: Noncontact near-infrared spectroscopy with image acquisition, interpretation and report, first anatomic site


name: Noncontact near-infrared spectroscopy (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation), other than for screening for peripheral arterial disease, image acquisition, interpretation, and report; each additional anatomic site (List separately in addition to code for primary procedure)


name: Noncontact near-infrared spectroscopy with image acquisition, interpretation and report, each additional anatomic site


name: Noncontact near-infrared spectroscopy (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation), for screening for peripheral arterial disease, including provocative maneuvers, image acquisition, interpretation, and report, one or both lower extremities


name: Noncontact near-infrared spectroscopy with provocative maneuvers, image acquisition, interpretation and report for screening for peripheral arterial disease


name: Removal of pulse generator for wireless cardiac stimulator for left ventricular pacing


name: Removal of pulse generator for wireless cardiac stimulator for left ventricular pacing; both components (battery and transmitter)


name: Removal of battery and transmitter of wireless cardiac stimulator for pacing of left lower chamber of heart


name: Relocation of pulse generator for wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming


name: Relocation of pulse generator for wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming; battery component only


name: Relocation of battery of wireless cardiac stimulator for pacing of left lower chamber of heart


name: Relocation of pulse generator for wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming; transmitter component only


name: Relocation of transmitter of wireless cardiac stimulator for pacing of left lower chamber of heart


name: Removal and replacement of pulse generator for wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming


name: Removal and replacement of pulse generator battery and transmitter of wireless heart stimulator system for pacing of lower left chamber of heart


name: Removal and replacement of pulse generator battery of wireless heart stimulator system for pacing of lower left chamber of heart


name: Implantation or replacement of posterior tibial nerve stimulating system for bladder dysfunction, accessed through skin


name: Revision or removal of posterior tibial nerve stimulating system for bladder dysfunction, accessed through skin


name: Electronic analysis with simple programming of posterior nerve stimulating system for bladder dysfunction


name: Electronic analysis with complex programming of posterior tibial nerve stimulating system for bladder dysfunction


name: Anterior lumbar or thoracolumbar vertebral body tethering


name: Tethering of 7 or fewer lower spine bones


name: Tethering of 8 or more lower spine bones


name: Revision (eg, augmentation, division of tether), replacement, or removal of thoracolumbar or lumbar vertebral body tethering, including thoracoscopy, when performed


name: Revision, replacement, or removal of lower spine tethering


name: Digitization of glass microscope slides for cytopathology, fluids, washings, or brushings, except cervical or vaginal


name: Digitization of glass microscope slides for cytopathology, fluids, washings, or brushings, except cervical or vaginal; smears with interpretation (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for cytopathology of fluids, washings, or brushings, smears


name: Digitization of glass microscope slides for cytopathology, fluids, washings, or brushings, except cervical or vaginal; simple filter method with interpretation (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for cytopathology of fluids, washings, or brushings, simple filter method


name: Digitization of glass microscope slides for cytopathology, concentration technique, smears, and interpretation (eg, Saccomanno technique) (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for cytopathology, concentration technique


name: Digitization of glass microscope slides for cytopathology, selective-cellular enhancement technique with interpretation (eg, liquid-based slide preparation method), except cervical or vaginal (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for cytopathology, selective-cellular enhancement technique


name: Digitization of glass microscope slides for cytopathology, cervical or vaginal (any reporting system), requiring interpretation by physician (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for cytopathology of cervical or vaginal specimen


name: Digitization of glass microscope slides for cytopathology, smears, any other source


name: Digitization of glass microscope slides for cytopathology, smears, any other source; screening and interpretation (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for cytopathology, smears requiring screening and interpretation


name: Digitization of glass microscope slides for cytopathology, smears, any other source; preparation, screening and interpretation (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for cytopathology, smears requiring preparation, screening and interpretation


name: Digitization of glass microscope slides for cytopathology, smears, any other source; extended study involving over 5 slides and/or multiple stains (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for cytopathology, smears requiring extended study of over 5 slides and/or multiple stains


name: Digitization of glass microscope slides for cytopathology evaluation of fine needle aspirate


name: Digitization of glass microscope slides for cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine adequacy for diagnosis, first evaluation episode, each site (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for cytopathology evaluation of fine needle aspirate, first evaluation


name: Digitization of glass microscope slides for cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine adequacy for diagnosis, each separate additional evaluation episode, same site (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for cytopathology evaluation of fine needle aspirate, each additional evaluation


name: Digitization of glass microscope slides for cytopathology, evaluation of fine needle aspirate; interpretation and report (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for consultation and report on referred slides prepared elsewhere (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for consultation and report on referred material requiring preparation of slides (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for consultation, comprehensive, with review of records and specimens, with report on referred material (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for consultation, comprehensive review


name: Digitization of glass microscope slides for pathology consultation during surgery


name: Digitization of glass microscope slides for pathology consultation during surgery; first tissue block, with frozen section(s), single specimen (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for pathology consultation during surgery, first tissue block


name: Digitization of glass microscope slides for pathology consultation during surgery; each additional tissue block with frozen section(s) (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for pathology consultation during surgery, each additional tissue block


name: Digitization of glass microscope slides for pathology consultation during surgery; cytologic examination (eg, touch preparation, squash preparation), initial site (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for pathology consultation during surgery; cytologic examination (eg, touch preparation, squash preparation), each additional site (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for immunofluorescence, per specimen


name: Digitization of glass microscope slides for immunofluorescence, per specimen; initial single antibody stain procedure (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for immunofluorescence, initial single antibody stain procedure


name: Digitization of glass microscope slides for immunofluorescence, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for immunofluorescence, each additional antibody stain procedure


name: Digitization of glass microscope slides for examination and selection of retrieved archival (ie, previously diagnosed) tissue(s) for molecular analysis (eg, KRAS mutational analysis) (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for in situ hybridization (eg, FISH), per specimen


name: Digitization of glass microscope slides for in situ hybridization (eg, FISH), per specimen; initial single probe stain procedure (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for in situ hybridization, initial single probe stain procedure


name: Digitization of glass microscope slides for in situ hybridization (eg, FISH), per specimen; each additional single probe stain procedure (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for in situ hybridization, each additional single probe stain procedure


name: Digitization of glass microscope slides for in situ hybridization (eg, FISH), per specimen; each multiplex probe stain procedure (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for in situ hybridization, each multiplex probe stain procedure


name: Digitization of glass microscope slides for morphometric analysis, in situ hybridization (quantitative or semiquantitative), manual, per specimen


name: Digitization of glass microscope slides for morphometric analysis, in situ hybridization (quantitative or semiquantitative), manual, per specimen; initial single probe stain procedure (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for morphometric analysis, in situ hybridization, initial manual single probe stain procedure


name: Digitization of glass microscope slides for morphometric analysis, in situ hybridization (quantitative or semiquantitative), manual, per specimen; each additional single probe stain procedure (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for morphometric analysis, in situ hybridization, each additional manual single probe stain procedure


name: Digitization of glass microscope slides for morphometric analysis, in situ hybridization (quantitative or semiquantitative), manual, per specimen; each multiplex probe stain procedure (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for morphometric analysis, in situ hybridization, each manual multiplex probe stain procedure


name: Digitization of glass microscope slides for blood smear, peripheral, interpretation by physician with written report (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for peripheral blood smear


name: Digitization of glass microscope slides for bone marrow, smear interpretation (List separately in addition to code for primary procedure)


name: Digitization of glass microscope slides for bone marrow smear


name: Digitization of glass microscope slides for electron microscopy, diagnostic (List separately in addition to code for primary procedure)


name: Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral nerve, with identification and marking of the treatment location, including noninvasive electroneurographic localization (nerve conduction localization), when performed


name: Insertion or replacement of percutaneous electrode array, spinal, with integrated neurostimulator, including imaging guidance, when performed


name: Insertion or replacement of spinal integrated nerve stimulating system with electrode array, accessed through the skin


name: Revision or removal of neurostimulator electrode array, spinal, with integrated neurostimulator


name: Revision or removal of spinal integrated nerve stimulating system with electrode array


name: Insertion or replacement of percutaneous electrode array, sacral, with integrated neurostimulator, including imaging guidance, when performed


name: Insertion or replacement of sacral integrated never stimulating system with electrode array, accessed through the skin


name: Revision or removal of neurostimulator electrode array, sacral, with integrated neurostimulator


name: Revision or removal of sacral integrated nerve stimulating system with electrode array


name: Electronic analysis with simple programming of implanted integrated neurostimulation system (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, spinal cord or sacral nerve, 1-3 parameters


name: Electronic analysis with simple programming of spinal or sacral integrated nerve stimulating system


name: Electronic analysis with complex programming of implanted integrated neurostimulation system (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, spinal cord or sacral nerve, 4 or more parameters


name: Electronic analysis with complex programming of spinal or sacral integrated nerve stimulating system


name: Motor-cognitive, semi-immersive virtual reality-facilitated gait training, each 15 minutes (List separately in addition to code for primary procedure)


name: Semi-immersive virtual reality-facilitated, motor-cognitive training for walking, each 15 minutes


name: Application of silver diamine fluoride 38%, by a physician or other qualified health care professional


name: Percutaneous transcatheter thermal ablation of nerves innervating the pulmonary arteries, including right heart catheterization, pulmonary artery angiography, and all imaging guidance


name: Pharmaco-oncologic Algorithmic Treatment Ranking


name: Patient-specific, assistive, rules-based algorithm for ranking pharmaco-oncologic treatment options based on the patient's tumor-specific cancer marker information obtained from prior molecular pathology, immunohistochemical, or other pathology results which have been previously interpreted and reported separately


name: Patient-specific, assistive, rules-based algorithm for ranking cancer drug treatment options based on the patient's tumor-specific cancer marker information obtained from previous laboratory testing which have been previously interpreted and reported separately


name: Transcatheter insertion of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed


name: Transcatheter insertion of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; complete system (ie, right atrial and right ventricular pacemaker components)


name: Transcatheter insertion of permanent dual-chamber leadless pacemaker using fluoroscopy and device interrogation of right atrial and right ventricular pacemaker components


name: Transcatheter insertion of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; right atrial pacemaker component (when an existing right ventricular single leadless pacemaker exists to create a dual-chamber leadless pacemaker system)


name: Transcatheter insertion of permanent dual-chamber pacemaker using fluoroscopy and device interrogation of right atrial pacemaker component


name: Transcatheter insertion of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; right ventricular pacemaker component (when part of a dual-chamber leadless pacemaker system)


name: Transcatheter insertion of a permanent dual chamber leadless pacemaker using fluoroscopy and device interrogation of right ventricular pacemaker component


name: Transcatheter removal of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography), when performed


name: Transcatheter removal of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography), when performed; complete system (ie, right atrial and right ventricular pacemaker components)


name: Transcatheter removal of the right atrial and right ventricular components of a permanent dual-chamber leadless pacemaker using fluoroscopy


name: Transcatheter removal of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography), when performed; right atrial pacemaker component


name: Transcatheter removal of the right atrial component of a permanent dual-chamber leadless pacemaker using fluoroscopy


name: Transcatheter removal of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography), when performed; right ventricular pacemaker component (when part of a dual-chamber leadless pacemaker system)


name: Transcatheter removal of the right ventricular component of a permanent dual-chamber leadless pacemaker using fluoroscopy


name: Transcatheter removal and replacement of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed


name: Transcatheter removal and replacement of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; dual-chamber system (ie, right atrial and right ventricular pacemaker components)


name: Transcatheter removal and replacement of permanent dual-chamber leadless pacemaker using fluoroscopy and device interrogation of right atrial and right ventricular components


name: Transcatheter removal and replacement of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; right atrial pacemaker component


name: Transcatheter removal and replacement of permanent dual-chamber leadless pacemaker using fluoroscopy and device interrogation of right atrial component


name: Transcatheter removal and replacement of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; right ventricular pacemaker component (when part of a dual-chamber leadless pacemaker system)


name: Transcatheter removal and replacement of permanent dual-chamber leadless pacemaker using fluoroscopy and device interrogation of right ventricular component


name: Programming device evaluation (in person) with iterative adjustment of implantable device to test the function of device and to select optimal permanent programmed values, with analysis, review, and report, by a physician or other qualified health care professional, leadless pacemaker system in dual cardiac chambers


name: In-person programming device evaluation of dual-chamber leadless pacemaker with adjustment of the device to test function and to select optimal permanent values, with analysis, review and report by a physician or other qualified health care professional


name: Transcatheter superior and inferior vena cava prosthetic valve implantation (ie, caval valve implantation [CAVI])


name: Transcatheter superior and inferior vena cava prosthetic valve implantation (ie, caval valve implantation [CAVI]); percutaneous femoral vein approach


name: Implantation of a superior and inferior vena cava artificial valve using the femoral vein through the skin


name: Transcatheter superior and inferior vena cava prosthetic valve implantation (ie, caval valve implantation [CAVI]); open femoral vein approach


name: Open implantation of a superior and inferior vena cava artificial valve using the femoral vein


name: Pulmonary tissue ventilation analysis using software-based processing of data from separately captured cinefluorograph images


name: Pulmonary tissue ventilation analysis using software-based processing of data from separately captured cinefluorograph images; in combination with previously acquired computed tomography (CT) images, including data preparation and transmission, quantification of pulmonary tissue ventilation, data review, interpretation and report


name: Analysis of lung tissue ventilation using software-based processing of cinefluorography images and previously acquired CT images, including data preparation and transmission, evaluation of lung tissue ventilation data, review, interpretation, and report


name: Pulmonary tissue ventilation analysis using software-based processing of data from separately captured cinefluorograph images; in combination with computed tomography (CT) images taken for the purpose of pulmonary tissue ventilation analysis, including data preparation and transmission, quantification of pulmonary tissue ventilation, data review, interpretation and report


name: Analysis of lung tissue ventilation using software-based processing of cinefluorography images and CT images taken for the purpose of lung tissue ventilation analysis, including data preparation and transmission, evaluation of lung tissue ventilation data, review, interpretation, and report


name: Subretinal injection of a pharmacologic agent, including vitrectomy and 1 or more retinotomies


name: Subretinal injection of a drug, including vitrectomy and retinotomy


name: Remote multi-day complex uroflowmetry (eg, calibrated electronic equipment)


name: Remote multi-day complex uroflowmetry (eg, calibrated electronic equipment); set-up and patient education on use of equipment


name: Set-up and education on use of equipment for remoted electronic assessment of bladder emptying


name: Remote multi-day complex uroflowmetry (eg, calibrated electronic equipment); device supply with automated report generation, up to 10 days


name: Device supply and report generation for remote electronic assessment of bladder emptying for up to 10 days


name: Esophagogastroduodenoscopy, flexible, transoral, with volume adjustment of intragastric bariatric balloon


name: Volume adjustment of intragastric bariatric balloon using a flexible endoscope through the mouth


name: Percutaneous injection of calcium-based biodegradable osteoconductive material, proximal femur, including imaging guidance, unilateral


name: Injection through the skin of calcium-based osteoconductive material to repair upper thigh bone


name: Ultrasound-based radiofrequency echographic multi-spectrometry (REMS), bone-density study and fracture-risk assessment, 1 or more sites, hips, pelvis, or spine


name: Ultrasound-based radiofrequency echographic multi-spectrometry scan for measuring bone loss in hips, pelvis, or spine


name: Open insertion or replacement of integrated neurostimulation system for bladder dysfunction including electrode(s) (eg, array or leadless), and pulse generator or receiver, including analysis, programming, and imaging guidance, when performed, posterior tibial nerve


name: Open insertion or replacement of integrated neurostimulation system for bladder dysfunction including electrode(s) (eg, array or leadless), and pulse generator or receiver, including analysis, programming, and imaging guidance, when performed, posterior tibial nerve; subcutaneous


name: Insertion or replacement of integrated posterior tibial nerve stimulating system under the skin, for bladder dysfunction


name: Open insertion or replacement of integrated neurostimulation system for bladder dysfunction including electrode(s) (eg, array or leadless), and pulse generator or receiver, including analysis, programming, and imaging guidance, when performed, posterior tibial nerve; subfascial


name: Insertion or replacement of integrated posterior tibial nerve stimulating system under muscle, for bladder dysfunction


name: Revision or removal of integrated neurostimulation system for bladder dysfunction, including analysis, programming, and imaging, when performed, posterior tibial nerve


name: Revision or removal of integrated neurostimulation system for bladder dysfunction, including analysis, programming, and imaging, when performed, posterior tibial nerve; subcutaneous


name: Revision or removal of integrated posterior nerve stimulating system under skin, for bladder dysfunction


name: Revision or removal of integrated neurostimulation system for bladder dysfunction, including analysis, programming, and imaging, when performed, posterior tibial nerve; subfascial


name: Revision or removal of integrated posterior nerve stimulating system under muscle, for bladder dysfunction


name: Continuous in-person monitoring and intervention (eg, psychotherapy, crisis intervention), as needed, during psychedelic medication therapy


name: Continuous in-person monitoring and intervention (eg, psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; first physician or other qualified health care professional, each hour


name: Continuous in-person monitoring and intervention (eg, psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; second physician or other qualified health care professional, concurrent with first physician or other qualified health care professional, each hour (List separately in addition to code for primary procedure)


name: Continuous in-person monitoring and intervention (eg, psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; clinical staff under the direction of a physician or other qualified health care professional, concurrent with first physician or other qualified health care professional, each hour (List separately in addition to code for primary procedure)


name: Continuous in-person monitoring and intervention during psychedelic medication therapy clinical staff working with the first physician or other qualified health care professional, each hour


name: Transcatheter insertion of permanent single-chamber leadless pacemaker, right atrial, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography and/or right ventriculography, femoral venography, cavography) and device evaluation (eg, interrogation or programming), when performed


name: Insertion of permanent single-chamber leadless pacemaker for pacing the right upper heart chamber using imaging guidance


name: Transcatheter removal of permanent single-chamber leadless pacemaker, right atrial, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography and/or right ventriculography, femoral venography, cavography), when performed


name: Removal of permanent single-chamber leadless pacemaker for pacing the right upper chamber of the heart using imaging guidance